BMS–Pfizer expands Eliquis access through Cost Plus Drug setting $345 monthly price

The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Merck wins FDA priority review for KEYTRUDA bladder cancer combo expansion

If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev

Experts endorse low-sodium salt substitutes to cut India’s hypertension burden

Consensus calls for nationwide adoption of potassium-enriched salt to reduce cardiovascular disease risk

Teva launches Home Ground platform to tackle isolation in schizophrenia care

The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping

Alexion to showcase broad neurology pipeline at AAN 2026 with 20 presentations

The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies

FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

EMA gives green light to warmer & simpler delivery rules for Wegovy injection

Novo Nordisk continues to position Wegovy as a cornerstone of its obesity treatment portfolio

Eli Lilly launches once-daily weight-loss pill Foundayo

The once-daily oral medication is approved for adults with obesity or overweight who have weight-related medical conditions

ImmunityBio responds to FDA concerns over promotional content